According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three ... profile in the oral GLP-1 space,” he said.

Lilly's R&D pipeline reveals that mazdutide is in phase 2 outside China. Meanwhile, other companies looking at combined GLP-1/glucagon agonists include Boehringer Ingelheim and Zealand Pharma ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

The GLP-1 segment is a very important class of drugs ... mainly due to its solid pipeline potential, particularly its obesity drugs. The stock is also trading above its 200-day moving average ...

As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

Eli Lilly and Company (LLY), one of the world’s largest pharmaceutical companies, boasts a diversified product profile. Lilly has consistently reported strong revenues and profits. It has seen ...